|
|
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
|
|
|
| 2020 | 2021 | Delta | | Generic Products | 253.05 | 55.4% | 204.60 | 51.1% | -19.14% |
| Metrics Contract Services | 82.82 | 18.1% | 82.09 | 20.5% | -0.89% |
| Specialty Products | 78.76 | 17.2% | 71.34 | 17.8% | -9.43% |
| Mayne Pharma International | 42.36 | 9.3% | 42.76 | 10.7% | +0.95% |
| AUD in Million |
|
|
|
| 2020 | 2021 | Delta | | United States | 414.63 | 90.7% | 358.02 | 89.3% | -13.65% |
| Australia | 28.24 | 6.2% | 29.82 | 7.4% | +5.59% |
| Other | 9.31 | 2% | 7.78 | 1.9% | -16.47% |
| Asia | 4.80 | 1.1% | 5.16 | 1.3% | +7.47% |
| AUD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,764,840,757 |
1,362,534,340 |
77.2% |
0 |
0.0% |
77.2% |
|
|
|
| Name | Equities | % | | Mithra Pharmaceuticals SA | 168,872,626 |
9.57% | | Investors Mutual Ltd. | 125,723,514 |
7.12% | | Bruce Mathieson | 105,577,583 |
5.98% | | Lazard Asset Management Pacific Co. | 104,006,124 |
5.89% | | APG Asset Management NV | 45,960,108 |
2.60% | | The Vanguard Group, Inc. | 38,385,937 |
2.18% | | Dimensional Fund Advisors LP | 32,733,449 |
1.85% | | Scott Richards | 32,213,061 |
1.83% | | Norges Bank Investment Management | 23,586,559 |
1.34% | | Vanguard Investments Australia Ltd. | 21,296,621 |
1.21% |
|
|
|
| Name | Equities | % | Valuation |
| INHIBITOR THERAPEUTICS, INC. (INTI) |
204,083,227 |
54.2% |
34,694,149 USD |
| HEDGEPATH PHARMACEUTICALS, INC. |
5,797,102 |
100.0% |
985,507 USD |
|
| Company contact information |
|
Mayne Pharma Group Ltd. 1538 Main North Road Salisbury South Salisbury, South Australia (SA) 5106 Phone : +61.8.8209.2666 Fax : +61.8.8281.0284 Web : http://www.maynepharma.com |
|
|
Sector Generic Pharmaceuticals
| | 1st jan. | Capi. (M$) |
 | MAYNE PHARMA GROUP LIMITED | -10.14% | 406 |
| | | |
 | SUN PHARMACEUTICAL INDUSTRIES LTD. | 42.03% | 26 913 |
 | OTSUKA HOLDINGS CO., LTD. | 9.78% | 23 042 |
 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. | -6.59% | 18 446 |
| ONO PHARMACEUTICAL CO., LTD. | -20.80% | 10 762 |
| ZHEJIANG NHU COMPANY LTD. | -8.54% | 10 286 |
| CIPLA LIMITED | 11.15% | 9 802 |
 | ASPEN PHARMACARE HOLDINGS LIMITED | 97.83% | 7 720 |
| CADILA HEALTHCARE LIMITED | 14.13% | 7 427 |
 | RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT. | 15.12% | 5 134 |
| SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | -1.34% | 4 842 |
 | CHINA MEDICAL SYSTEM HOLDINGS LIMITED | 66.97% | 4 581 |
| TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. | -5.76% | 4 579 |
| SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. | -9.03% | 4 302 |
 | KRKA, D. D. | 22.54% | 4 051 |
| SICHUAN KELUN PHARMACEUTICAL CO., LTD. | -6.07% | 4 006 |
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | -6.91% | 3 357 |
| YIFAN PHARMACEUTICAL CO., LTD. | -15.00% | 3 086 |
| HAISCO PHARMACEUTICAL GROUP CO., LTD. | -1.83% | 2 843 |
 | HANMI PHARM. CO., LTD. | -26.19% | 2 741 |
| AJANTA PHARMA LIMITED | 35.65% | 2 556 |
Connections : Mayne Pharma Group Limited |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
